Raj Chovatiya, MD, PhD, on Investigating HSV-1 Vectors in Collagen-Based Disorders

Commentary
Video

The assistant professor dermatology at the Northwestern University Feinberg School of Medicine discussed the potential for further research enabled by B-VEC.

“In this circumstance, it's a modified viral vector to really try to tamp down on the things that we don't want. And so, I think that this gives credence for this particular viral vector for delivery of other genes and other cutaneous disorders that arise from mutations that might be correctable.”

Krystal Biotech’s beremagene geperpavec (B-VEC), approved in the United States in May 2023 for treating dystrophic epidermolysis bullosa (DEB) under the name Vyjuvek, now has a marketing authorization application up for review in the European Union.1,2

B-VEC is topically applied in a gel droplet form to the skin and is redosable, with caregivers applying it to wounds on a weekly basis, making it unique among investigational and approved gene therapies. DEB is caused by mutations in COL7A1, which encodes for collagen 7 protein, and which is delivered by B-VEC's herpes simplex virus type 1 (HSV-1) vector rather than an adeno-associated virus (AAV) vector. The target may have potential to be investigated for other disorders in which COL7A1 is impacted, and the HSV-1 vector may have wide applicability as well.

CGTLive® spoke with Raj Chovatiya, MD, PhD, assistant professor dermatology at the Northwestern University Feinberg School of Medicine, to learn more about the potential advantages of the HSV-1 vector over traditional AAV vectors and the potential for expansion into other collagen-based disorders.

REFERENCES
1. Krystal Biotech announces EMA validation of marketing authorization application for VYJUVEK for the treatment of dystrophic epidermolysis bullosa. News release. Krystal Biotech, Inc. November 27, 2023. Accessed November 27, 2023. https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-ema-validation-marketing-authorization
2. Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagenegeperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa. News release. Krystal Biotech. May 19, 2023. Accessed November 27, 2023. https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-receives-fda-approval-first-ever-redosable-gene
Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.